Skip to Content

Generic Xhance Availability

Xhance is a brand name of fluticasone nasal, approved by the FDA in the following formulation(s):

XHANCE (fluticasone propionate - spray, metered;nasal)

  • Manufacturer: OPTINOSE US INC
    Approval date: September 18, 2017
    Strength(s): 0.093MG [RLD]

Has a generic version of Xhance been approved?

No. There is currently no therapeutically equivalent version of Xhance available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xhance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Nasal delivery device
    Patent 6,715,485
    Issued: April 6, 2004
    Inventor(s): Per Gisle; Djupesland
    Assignee(s): OptiNose AS

    A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril.

    Patent expiration dates:

    • March 3, 2020
      ✓ 
      Drug product
  • Nasal devices
    Patent 7,975,690
    Issued: July 12, 2011
    Inventor(s): Djupesland; Per Gisle
    Assignee(s): OptiNose AS

    The present invention relates to a nasal delivery device for and a method of delivering a substance, in particular one of a liquid, as a suspension or solution, or a powder containing a medicament, especially systemic or topical pharmaceuticals, or a vaccine to the nasal airway of a subject.

    Patent expiration dates:

    • December 29, 2025
      ✓ 
      Patent use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
  • Nasal delivery method
    Patent 8,327,844
    Issued: December 11, 2012
    Inventor(s): Djupesland; Per Gisle
    Assignee(s): OptiNose AS

    A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril.

    Patent expiration dates:

    • October 8, 2023
      ✓ 
      Patent use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
  • Nasal devices
    Patent 8,522,778
    Issued: September 3, 2013
    Assignee(s): OptiNose AS

    A nasal delivery device for and a method of delivering a substance to a nasal cavity of a subject, the delivery device including: a nosepiece for fitting to a nostril of a subject; a substance supply unit for supplying a substance for delivery through the nosepiece; and a delivery prevention mechanism for preventing delivery of a substance through the nosepiece until the nosepiece is properly fitted to the nostril of the subject.

    Patent expiration dates:

    • May 11, 2022
      ✓ 
      Drug product
  • Nasal delivery
    Patent 8,550,073
    Issued: October 8, 2013
    Assignee(s): OptiNose AS

    A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit (20, 24) including a nosepiece (17) for fitting to a nostril of a subject and a nozzle (45) through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity, wherein at least a tip element of the nosepiece has, at least in one configuration, an elongate lateral section which has a longer dimension in a first, sagittal direction than a second direction orthogonal to the sagittal direction, such that, when the nosepiece is inserted in the nasal cavity of the subject, the longer dimension of the nosepiece acts to engage lower and upper surfaces of the nasal cavity, preferably at the nasal valve, and expand the same in the sagittal plane; and a delivery unit (43, 49, 51) for delivering substance through the nozzle of the nosepiece.

    Patent expiration dates:

    • October 22, 2029
      ✓ 
      Drug product
  • Nasal delivery device
    Patent 8,555,878
    Issued: October 15, 2013
    Assignee(s): OptiNose AS

    A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril.

    Patent expiration dates:

    • March 20, 2020
      ✓ 
      Drug product
  • Nasal delivery
    Patent 8,978,647
    Issued: March 17, 2015
    Assignee(s): Optinose, AS

    A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece for fitting to a nostril of a subject, wherein the nosepiece comprises a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered such as to be inclined to a longitudinal axis of the nosepiece, with the delivery aperture extending both laterally across the tip element and along a longitudinal extent of the tip element; a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity; and a delivery unit for delivering substance through the nozzle of the nosepiece.

    Patent expiration dates:

    • August 6, 2030
      ✓ 
      Drug product
  • Nasal delivery device
    Patent 9,072,857
    Issued: July 7, 2015
    Assignee(s): OptiNose AS

    A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril.

    Patent expiration dates:

    • April 10, 2021
      ✓ 
      Drug product
  • Nasal delivery
    Patent 9,468,727
    Issued: October 18, 2016
    Assignee(s): OptiNose AS

    A nasal delivery device for and a method of delivering a substance to a nasal cavity of a subject, the delivery device comprising: a delivery unit for delivering a flow entraining a substance to one nostril of a subject, the delivery unit including a nosepiece for fitting to a nostril of the subject; and a flow resistor unit for fitting to the other nostril of the subject, the flow resistor unit including a progressive resistor for progressively providing an increasing flow resistance to the delivered flow.

    Patent expiration dates:

    • July 30, 2020
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • September 18, 2020 - NEW PRODUCT
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide